WebNov 2, 2010 · Assignee: Diakron Pharmaceuticals, Inc. Inventors: Reguri Buchi Reddy, Upparapalli Sampathkumar, Nilam Sahu, Jawaji Karunakara Rao, Gade Brahma Reddy PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES. Publication number: 20110105753 ... WebJul 28, 2024 · LONDON, July 28, 2024 /PRNewswire/ --. Antithrombotic Drugs Market 2024-2027: Anticoagulants, Antiplatelets, Fibrinolytics The revenue of the antithrombotic drugs …
Diakron Pharmaceuticals Inc Company Profile, Financial and …
WebCompanies like Diakron Pharmaceuticals. Similar companies and competitors including the VentureRadar Innovation and Growth scores, Company Information, Location and more. All; ... Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily ... WebAug 13, 2008 · Diakron Pharmaceuticals, Inc. is a privately-owned pharmaceutical company specializing in the development of products for the treatment of certain cardiovascular … fix timetable problems monash
Diakron Pharmaceuticals
WebNov 18, 2011 · DPOC-4088 is an orally active, potent, rapidly binding, reversible direct thrombin inhibitor (DTI) being developed as a once-a-day alternative to warfarin for primary prevention of venous thromboembolism. Objectives: WebJul 19, 2012 · February 23, 2015 updated by: Diakron Pharmaceuticals. A Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics (PK), Pharmacodynamics (PD), PK/PD Characteristics and Safety of Multiple Once-daily Oral Dosing of DPOC-4088 in Healthy Young Male Subjects ... WebMcKesson Corp. USA Listed McKesson Corporation delivers pharmaceuticals, medical supplies, and health care information technologies to the healthcare industry in the … canning news